Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:bcr08.2008.0691.
doi: 10.1136/bcr.08.2008.0691. Epub 2009 May 12.

Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report

Joaquin De Haro  1 , Aurora Florez, Jose Luis Fernandez, Francisco Acin
Affiliations

Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report

Joaquin De Haro et al. BMJ Case Rep. 2009.

Abstract

Buerger disease (thromboangiitis obliterans) is a non-atherosclerotic segmental inflammatory disease strongly associated with tobacco use, and it affects small and medium-sized blood vessels in the upper and lower extremities. The only known treatment for this disease is complete discontinuation of tobacco use. This report describes the case history of a woman with Buerger disease treated with the oral dual endothelin receptor antagonist bosentan. It is believed that this is the first description in the literature of this use for bosentan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Digital ulcers before treatment with bosentan.
Figure 2
Figure 2
Magnetic resonance angiography of the lower limbs. Segmental occlusions of the pedal arteries and corkscrew collateral arteries were found.
Figure 3
Figure 3
Trophic lesions healed completely after treatment with dual endothelin-1 receptor antagonist.
See this image and copyright information in PMC

References

    1. Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Circulation 1990; 82(5 Suppl): IV3–8 - PubMed
    1. Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger’s disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 1997; 13: 186–92 - PubMed
    1. Agarwal VK. Long-term results of omental transplantation in chronic occlusive arterial disease (Buerger’s disease) and retinal avascular diseases (retinitis pigmentosa). Int Surg 2007; 92: 174–83 - PubMed
    1. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med 2000; 343: 864–9 - PubMed
    1. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985–93 - PubMed

LinkOut - more resources